Peer to Peer

Addressing Patient Concerns About Treatment Safety Data

Steven R. Feldman, MD, PhD, is from the Wake Forest University School of Medicine, Winston-Salem, North Carolina.

In this edition of the “Peer to Peer” audiocast series, Dr. Vincent DeLeo speaks with Dr. Steven Feldman about treatment compliance and addressing patient concerns about treatment safety data. They discuss strategies for reassuring patients about risks associated with biologics for psoriasis and other drugs, particularly risks patients may read about on the Internet.


 

Recommended Reading

Infliximab biosimilar posts mostly reassuring data in Norway’s NOR-SWITCH study
Psoriasis Collection
Pediatric psoriasis linked to multiple psychiatric comorbidities
Psoriasis Collection
Update on New Drugs in Dermatology
Psoriasis Collection
VIDEO: Tune in to psoriasis patients’ quality of life
Psoriasis Collection
Fighting back against psoriasis bullies
Psoriasis Collection
Study finds etanercept biosimilar safe and effective in patients with severe plaque psoriasis
Psoriasis Collection
Spot Psoriatic Arthritis Early in Psoriasis Patients
Psoriasis Collection
Psoriasis Treatment Considerations in Military Patients: Unique Patients, Unique Drugs
Psoriasis Collection
Psoriasis and Internal Disease: Report From the Mount Sinai Winter Symposium
Psoriasis Collection
Latest ixekizumab safety data called ‘very reassuring’
Psoriasis Collection

Related Articles